INDP · Indaptus Therapeutics Inc
United States · RS rating 13 · As of 2026-10-14
| Price | 2.21 USD |
|---|---|
| 1-day change | -7.5% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 4 / 28 / 16 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 24 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +91.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.5% |
| Market cap (USD) | $7.1M |